SystemIc iNflammation and Microvascular diSease PreventIon in psoRiatic diseasE

NCT ID: NCT04417114

Last Updated: 2021-07-23

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE4
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-04-01
• Study Completion Date: 2025-03-31

Brief Summary

This is a single-label open-arm mechanistic clinical study recruiting patients with psoriasis or psoriatic arthritis with elevated cardiovascular risk. Subjects enrolled in this study will receive statin treatment with rosuvastatin. The statin treatment in this study will be used as an intervention with widely known pleiotropic CV risk reduction effects, including anti-inflammatory reduction. Subjects will be studied before statin therapy and followed for 48 weeks on treatment. The primary outcome will be change in the coronary flow reserve (CFR) as measured by cardiac PET. Overall, this study will examine the impact of statin therapy on changes in CFR as a reflection of impaired coronary vasoreactivity and a manifestation of myocardial ischemia, which may precede clinical CV events (and visible changes in plaque morphology) in high-risk patients with psoriatic disease.

Detailed Description

The primary objective of this study is to investigate the impact of maximally tolerated statin (MTS) therapy on coronary flow reserve (CFR), reflecting coronary vasoreactivity and myocardial tissue perfusion. Impaired CFR is a manifestation of myocardial ischemia which may precede clinical CV events (and visible changes in plaque morphology) in high-risk patients with psoriatic disease. From previous studies, it is known that traditional risk factors underestimate cardiovascular risk in psoriatic disease. The central hypothesis of this study, is that MTS therapy - which has known pleiotropic CV risk reduction effects, including anti-inflammatory properties -- will quantitatively improve myocardial blood flow and CFR as measured by positron emission tomography (PET) over one year and reduce atherosclerotic burden, in patients with moderate-severe psoriasis or psoriatic arthritis. In so doing, improvement in coronary vasoreactivity, endothelial function, and tissue perfusion may have beneficial effects on myocardial mechanics, left ventricular deformation and function and, ultimately, symptoms and prognosis.

Conditions

Psoriasis; Psoriatic Arthritis; Cardiovascular Risk Factor

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Single-Arm Open label

This is a single-arm open label mechanistic clinical trial. Subjects will be treated with rosuvastatin at a dose of 20mg/day and uptitrated as tolerated to a dose of 40mg/day.

Group Type: EXPERIMENTAL

Rosuvastatin

Intervention Type: DRUG

Statin

Interventions

Rosuvastatin

Statin

Intervention Type: DRUG

Other Intervention Names

Crestor

Eligibility Criteria

Inclusion Criteria

• Age > 40 years of age
• Documented evidence of PsO or PsA by a board-certified dermatologist or rheumatologist, respectively.
• Subjects on systemic therapy/phototherapy for PsO or PsA will be required to be on stable therapy for at least 3 months prior to enrollment

Plus, documented history of at least one of the following:

1. Hypertension

2. Obesity (BMI > 30)

3. Diabetes Mellitus

4. HsCRP > 3 mg/L within 30 days of enrollment

Exclusion Criteria

• Patients on statin or PCSK9 inhibitor therapy, or use of statin therapy within the past year
• Documented history of other systemic inflammatory diseases, which in the opinion of the investigator would be inappropriate for enrollment.
• Prior history of untreated chronic infection (tuberculosis), severe fungal infection, or known HIV positive, chronic hepatitis B or C infection), prior history of solid malignancy, myeloproliferative or lymphoproliferative disease within 5 years, excluding treated non-melanoma skin cancer
• NYHA class IV heart failure
• Active liver disease including unexplained, persistent elevations of serum transaminases or serum transaminase elevation > 3 x the upper limit of normal.
• Severe renal impairment
• Pregnancy

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The Cleveland Clinic

OTHER

Sponsor Role: collaborator

Brigham and Women's Hospital

OTHER

Sponsor Role: lead

Responsible Party

Marcelo F. Di Carli, MD, FACC

Chief Division of Nuclear Medicine and Molecular Imaging, Executive Director CV Imaging Program, Principal Investigator, Seltzer Family Professor of Radiology and Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Marcelo Di Carli, MD

Role: PRINCIPAL_INVESTIGATOR

Brigham and Women's Hospital

Other Identifiers

BWH TBD

Identifier Type: -

Identifier Source: org_study_id